<DOC>
	<DOCNO>NCT00020501</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give different way may kill tumor cell . It yet know chemotherapy regimen effective colorectal cancer spread liver . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without isolated hepatic perfusion melphalan treat patient colorectal cancer spread liver .</brief_summary>
	<brief_title>Chemotherapy With Without Isolated Hepatic Perfusion With Melphalan Treating Patients With Colorectal Cancer That Has Spread Liver</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free overall survival patient unresectable colorectal cancer metastatic liver treat regional systemic chemotherapy without isolated hepatic perfusion melphalan . - Compare response rate duration response patient treat regimen . - Compare pattern recurrence ( liver vs systemic ) patient treat regimen . - Compare health-related quality life ( QOL ) patient treat regimen . - Determine whether baseline QOL correlate length survival patient treat regimen . OUTLINE : This randomize study . Patients stratify accord prior chemotherapy liver metastasis ( yes v ) percentage hepatic replacement ( le 25 % v least 25 % ) . All patient undergo laparotomy determine final eligibility . Eligible patient randomize 1 2 treatment arm . - Arm I : Patients undergo hyperthermic isolated hepatic perfusion melphalan 60 minute . Patients undergo placement intrahepatic pump port . At 6 week post hepatic perfusion , patient receive systemic chemotherapy comprise irinotecan IV 90 minute day 1 follow fluorouracil IV 15 minute leucovorin calcium ( CF ) IV 15 minute day 1-3 . Patients receive local chemotherapy comprise floxuridine ( FUDR ) CF hepatic arterial infusion ( HAI ) continuously day 14-28 . - Arm II : Patients undergo placement intrahepatic pump port laparotomy . At 7 day post laparotomy , patient receive FUDR CF HAI continuously 14 day . Beginning 2 week completion HAI , patient receive systemic local chemotherapy arm I . Treatment combined systemic local chemotherapy repeat every 35 day maximum 6 course . Treatment local chemotherapy alone repeat every 28 day maximum 6 additional course absence disease progression unacceptable toxicity . Quality life assess baseline , postoperatively , every third course chemotherapy , every 3 month 2 year , every 6 month thereafter . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 168 patient ( 84 per treatment arm ) accrue study within 54 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic colorectal cancer parenchyma liver No evidence extrahepatic disease ( limited resectable extrahepatic disease allow ) Unresectable liver metastasis , define follow : More 3 site disease Bilobar disease Tumor abut major vascular ductal structure Measurable disease No biopsyproven cirrhosis evidence significant portal hypertension manifest ascites , esophageal varix , collateral vessel around organ drain portal venous system PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm^3 Hematocrit great 27.0 % WBC great 3,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL PT great 2 second upper limit normal Elevations transaminase secondary metastatic disease allow No venoocclusive disease No active chronic hepatitis Hepatitis B C allow provide evidence cirrhosis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No ischemic cardiac disease No prior congestive heart failure LVEF le 40 % Pulmonary : No chronic obstructive pulmonary disease chronic pulmonary disease pulmonary function test le 50 % predict Other : No active infection Not pregnant nursing Negative pregnancy test Weight great 30 kg PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy disease recover Chemotherapy : At least 4 week since prior chemotherapy disease recover No prior intrahepatic artery infusion therapy floxuridine Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy disease recover Surgery : Not specify Other : No concurrent immunosuppressive drug No concurrent chronic anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>